The science behind
LumbaCure®
Accelerate recovery
Support professionals
Suitable for all patients
Boost athletes performance
New clinical data in Q3 2025
Innovative robotic seat
- Addressing 3 targets: proprioception – muscle relaxion – mobilization
- Driven by a proprietary motion algorithm enabling monitored, controlled and reproducible physical sessions
- Unique mechanism of action imposing mobilization of the lower back, contrasting with passive solutions
- Designed with six degrees of freedom (three rotations and three translations), enabling full-spectrum spinal mobilization in all directions, far beyond the limited movement patterns offered by traditional therapy solutions.
- Providing pain management support and fostering mental engagement and motivation
New developments for Lumbacure®
We are advancing the LumbaCure® platform through:
- A new intelligent interface designed to support therapists with a clinical decision-making support system powered by real-time biofeedback and AI-driven analysis of patient data
- The expansion into new therapeutic fields beyond lower back pain, unlocking broader applications in musculoskeletal health
Clinical investigations demonstrating the value of LumbaCure®
Our LumbaCure® equipment is currently being evaluated through clinical investigations involving patients with low back pain in a variety of settings, from chronic conditions to elderly people
LumbaCure® timeline
LumbaCure® is currently in the clinical trial phase, advancing toward final engineering refinements. Comparative clinical data are published in the second half of 2025, with commercialization planned for the end of 2026 in the U.S. and the end of 2027 in the EU.
Early Clinical Trial:
Assessing the safety of LumbaCure®
Study dates
Participants
Study design
Prospective, single-arm, non-controlled, short-term study (3 sessions over 10 days) conducted across multiple sites in Belgium
Primary objective
To assess the safety profile and patient acceptability of LumbaCure® in individuals with chronic low back pain.
Key findings
- 96% of participants reported high acceptability of the intervention
- No serious adverse events or exacerbation of back pain were observed post-session
- The guided, active mobilization induced by LumbaCure® was consistently well tolerated, even among patients typically limited by pain-related fear of movement
- This trial marked the first step in validating LumbaCure® as a safe and effective rehabilitation solution.
Exploratory efficacy trial:
Evaluating LumbaCure’®s impact on pain and fall risk in elderly patients
Study NCT06203886
Participants
n = 10 elderly patients (>70 years) with chronic low back pain
Study design
Exploratory, non-controlled pilot study conducted in a rest and nursing home setting
Intervention
LumbaCure® sessions, 15 minutes, 3 times per week over 4 weeks
Primary objective
To assess the potential impact of LumbaCure® on pain reduction and functional mobility associated with fall risk.
Key findings
- After one month of intervention, over 50% of participants showed meaningful clinical improvement across multiple outcomes.
Specifically, 2 out of 7 participants improved on the Tinetti test, indicating reduced fall risk, and several others improved on the Timed Up and Go (TUG) testand the Numeric Pain Rating Scale (NPRS) for pain.
Overall, 3 out of 7 participants showed improvement on at least two of these three key measures (mobility, pain, and fall risk), demonstrating a positive therapeutic trend. - Despite its exploratory nature, this pilot study highlights LumbaCure®’s potential in improving functional outcomes among elderly individuals with chronic low back pain.
Exploratory efficacy trial:
Evaluating LumbaCure®’s impact on pain reduction in patients with chronic low back pain
Study NCT06138002
Study dates
First patient first visit – October 2, 2023 | Last patient last visit – September 12, 2024
Participants
n = 21 patients with chronic low back pain
Study design
Randomized, multi-site study comparing LumbaCure to standard physiotherapist-supervised exercise
Intervention
15-minute sessions, 3 times per week for 1 month
Primary objective
To compare the efficacy of LumbaCure® versus conventional physiotherapy exercises in managing chronic low back pain.
Key findings
- Trend showing better improvement in pain level in comparison to physical exercise
- Patient adherencewas markedly higher in the LumbaCure® group: only 20% of LumbaCure® users discontinued , compared to the 73% dropout in the control group following the transition to standard rehabilitation (2 hours, twice per week for 36 sessions)
These results suggest that LumbaCure® may play a key role in improving patient engagement and optimizing the effectiveness of multidisciplinary rehabilitation protocols for chronic low back pain.
Ongoing clinical study:
Validating LumbaCure® in chronic low back pain rehabilitation
Study NCT06662032
Study dates
First patient first visit – June 18, 2024 | Last patient last visit (expected) – June 3, 2025
Participants
n = 50 patients with chronic low back pain
Study design
Multi-site, randomized controlled trial embedded within a standard rehabilitation program (2 hours, twice per week for 36 sessions)
Primary objective
To evaluate the impact of integrating LumbaCure® into a conventional rehabilitation protocol for chronic low back pain.
Key outcomes being assessed
- Pain intensity
- Functional disability
- Quality of life
- Pain perception and fear of movement
- Treatment experience/satisfaction
Study design highlights
- Patients are randomized to either standard rehabilitation or standard rehabilitation with LumbaCure®
- LumbaCure® is delivered as a structured component within the broader therapeutic framework
This study is expected to generate pivotal data on the clinical value and added effectiveness of LumbaCure® when combined with multidisciplinary rehabilitation in chronic low back pain.